Lipid and glucose profiles in pregnant women with HIV on tenofovir-based antiretroviral therapy
Ahizechukwu C Eke,Sean S Brummel,Muktar H Aliyu,Lynda Stranix-Chibanda,George U Eleje,Ifeanyichukwu U Ezebialu,Violet Korutaro,Deo Wabwire,Allen Matubu,Tapiwa Mbengeranwa,Nahida Chakhtoura,Lameck Chinula,Katie McCarthy,Kevin Knowles,Chelsea Krotje,Macrae F Linton,Kelly E Dooley,Paul E Sax,Todd Brown,Shahin Lockman,IMPAACT 2010/VESTED Study Team,Sharon Nachman,James McIntyre,David P Harrington,Catherine Hill,Steven Joffe,Alwyn Mwinga,Andrew J Nunn,Haroon Saloojee,Merlin L Robb,Jonathan Kimmelman,Graeme A Meintjes,Barbara E Murray,Stuart Campbell Ray,Anastasios A Tsiatis,Paul A Volberding,David Glidden,Valeria Cavalcanti Rolla,Renee Browning,Jeanna Piper,Karin Klingman,Debika Bhattacharya,Patrick Jean-Philippe,Lynne Mofenson,Sean Brummel,Lauren Ziemba,Mauricio Pinilla,Chelsea Morroni,Benjamin Johnston,Scott McCallister,Jean van Wyk,Mark Mirochnick,Brookie Best,Kevin Robertson,Cheryl Blanchette,Nagawa Jaliaah,Andee Fox,Frances Whalen,William Murtaugh,Yao Cheng,Emmanuel Patras
DOI: https://doi.org/10.1093/cid/ciae441
2024-09-02
Abstract:Objective: Tenofovir alafenamide (TAF)-based antiretroviral therapy (ART) regimens have been associated with adverse changes in lipid and glucose profiles compared with tenofovir disoproxil fumarate (TDF)-based ART, but data in pregnancy is limited. We evaluated metabolic markers in pregnant women with HIV after starting TAF- vs TDF-based ART. Methods: We analyzed data within the IMPAACT 2010/VESTED trial, which demonstrated better pregnancy outcomes in pregnant women randomized to initiate TAF/Emtricitabine/Dolutegravir (TAF/FTC+DTG; n=217) or TDF/FTC+DTG (n=215). We measured non-fasting plasma concentrations of glucose, total-cholesterol, low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol (HDL-C), lipoprotein (a), and triglycerides from samples collected eight weeks after enrollment. We employed linear regression models to estimate by-arm mean differences. Results: 219 participants enrolled in the DTG arms in Zimbabwe and Uganda: 109 in the TAF/FTC+DTG and 110 in the TDF/FTC+DTG arms. At study entry, mean gestational age was 22.6 weeks, median HIV-1 RNA was 711 copies/mL, and mean age was 25.8 years. By eight weeks, mean total cholesterol was 12 mg/dL higher in women randomized to TAF/FTC+DTG versus TDF/FTC+DTG (95% CI 3.8, 21.1). Pregnant women in the TAF/FTC+DTG arm had higher mean LDL-C (7.1 mg/dL, 95% CI 0.2, 14.0), triglycerides (12.3 mg/dL, 95% CI 1.8, 22.7), lipoprotein (a) (7.3 mg/dL, 95% CI 1.1, 13.6), and lower mean HDL-C (2.8 mg/dL, 95% CI 0.1, 5.6) compared to the TDF/FTC+DTG arm. Conclusion: Pregnant women randomized to start TAF/FTC+DTG had higher lipids than those randomized to TDF/FTC+DTG within eight weeks of ART initiation. However, lipid levels were within normal reference ranges.